Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384711 | 0.87 | KLKB1 (0.41) | SMN1; SMN2PTPN1L3MBTL1KLKB1EPHX2 | |
| SCHEMBL27229801 | 0.74 | TACR1 (0.49) | SMN1; SMN2PTPN1L3MBTL1ALDH1A1TACR1 | |
| SCHEMBL24324560 | 0.74 | TACR1 (0.41) | SMN1; SMN2L3MBTL1KLKB1PDE10AALDH1A1 | |
| SCHEMBL23384776 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2PTPN1L3MBTL1KLKB1PDE10A | |
| SCHEMBL23384767 | 0.73 | TACR1 (0.45) | SMN1; SMN2L3MBTL1KLKB1ALDH1A1TACR1 | |
| SCHEMBL29339279 | 0.71 | GAA (0.50) | SMN1; SMN2EPHX2ALDH1A1TACR1 | |
| SCHEMBL29784651 | 0.69 | DYRK1A (0.43) | SMN1; SMN2L3MBTL1NAMPTTACR1 | |
| SCHEMBL31618677 | 0.68 | CYP4F2 (0.46) | SMN1; SMN2 | |
| SCHEMBL23384717 | 0.67 | NPC1 (0.52) | SMN1; SMN2PTPN1FAAHALDH1A1TACR1 | |
| SCHEMBL14672755 | 0.66 | TACR1 (0.60) | SMN1; SMN2EPHX2ALDH1A1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050653-A1 | ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, CYP11B1, CYP4A11 | SMN1; SMN2 4145/4885PTPN1 1603/4885L3MBTL1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.